Anticoagulants and their reversal.

In an exciting era with many alternatives to the old anticoagulants heparin and warfarin emerging on the scene, awareness of the possibility to reverse their effect is mandatory. In this review, the traditional antidotes for warfarin (vitamin K, plasma, and prothrombin complex concentrate) and for heparin (protamine) are described together with the newer alternatives (recombinant activated factor VII, concatameric peptides, and recombinant platelet factor 4). For some of the newer anticoagulants, possible antidotes have been identified, whereas other alternatives have been discarded. There is a very limited experience of deamino-d-arginine vasopressin or a von Willebrand factor VIII concentrate to counteract hirudin. The small direct thrombin inhibitors may be reversed with activated prothrombin complex concentrate but not with recombinant activated factor VII, whereas the latter agent appears to be effective against the pentasaccharides and the recombinant nematode anticoagulant protein C2. Additional options that may become available in the future are also discussed briefly.

[1]  R. Peters,et al.  Recombinant nematode anticoagulant protein c2, an inhibitor of the tissue factor/factor VIIa complex, in patients undergoing elective coronary angioplasty. , 2003, Journal of the American College of Cardiology.

[2]  E. Hylek,et al.  The risk of hemorrhage among patients with warfarin-associated coagulopathy. , 2006, Journal of the American College of Cardiology.

[3]  J. C. Sørensen,et al.  Reversal of the International Normalized Ratio with recombinant activated factor VII in central nervous system bleeding during warfarin thromboprophylaxis: clinical and biochemical aspects , 2003, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[4]  M Gent,et al.  Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. , 2003, The New England journal of medicine.

[5]  W. S. Akers,et al.  Recombinant Factor VIIa for Refractory Bleeding After Cardiac Surgery Secondary to Anticoagulation with the Direct Thrombin Inhibitor Lepirudin , 2006, Pharmacotherapy.

[6]  A. Jessel,et al.  Investigation of activated prothrombin complex concentrate as potential hirudin antidote in animal models. , 1995, Haemostasis.

[7]  L. Aledort Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity , 2004, Journal of thrombosis and haemostasis : JTH.

[8]  S. Ibbotson,et al.  The Influence of Infusions of 1-Desamino-8-D-Arginine vasopressin (DDAVP) In Vivo on the Anticoaguhht Effect of Recombinant Hirudin (CGP39393) In Vitro , 1991, Thrombosis and Haemostasis.

[9]  John Spandorfer,et al.  Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin: assessment of incidence, case-fatality rate, time course and sites of bleeding, and risk factors for bleeding. , 2006, Archives of internal medicine.

[10]  J. Douketis,et al.  Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomised controlled trial , 2000, The Lancet.

[11]  S. Malherbe,et al.  Argatroban as anticoagulant in cardiopulmonary bypass in an infant and attempted reversal with recombinant activated factor VII. , 2004, Anesthesiology.

[12]  G. Raskob,et al.  Hemorrhagic complications of anticoagulant treatment. , 1992, Chest.

[13]  M. Tarantino,et al.  The use of recombinant activated factor VII to reverse warfarin-induced anticoagulation in patients with hemorrhages in the central nervous system: preliminary findings. , 2003, Journal of neurosurgery.

[14]  V. Marder,et al.  DDAVP Reduces Bleeding during Continued Hirudin Administration in the Rabbit , 1996, Thrombosis and Haemostasis.

[15]  S. Yusuf,et al.  Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. , 2006, JAMA.

[16]  M. Brophy,et al.  Anaphylactoid Reactions to Vitamin K , 2001, Journal of Thrombosis and Thrombolysis.

[17]  R. Zimlichman,,et al.  Efficacy and safety of a prothrombin complex concentrate (Octaplex) for rapid reversal of oral anticoagulation. , 2004, Thrombosis research.

[18]  Salim Yusuf,et al.  Comparison of fondaparinux and enoxaparin in acute coronary syndromes. , 2006, The New England journal of medicine.

[19]  G. Raskob,et al.  Dose-Response Study of Recombinant Factor VIIa/Tissue Factor Inhibitor Recombinant Nematode Anticoagulant Protein c2 in Prevention of Postoperative Venous Thromboembolism in Patients Undergoing Total Knee Replacement , 2001, Circulation.

[20]  J. Duguid,et al.  Guidelines for the use of fresh‐frozen plasma, cryoprecipitate and cryosupernatant , 2004, British journal of haematology.

[21]  S. Carlsson,et al.  Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor. , 2001, Thrombosis research.

[22]  F. Depasse,et al.  Recombinant factor VIIa partially reverses the inhibitory effect of fondaparinux on thrombin generation after tissue factor activation in platelet rich plasma and whole blood , 2004, Thrombosis and Haemostasis.

[23]  P. D. de Groot,et al.  Recombinant factor VIIa reverses the in vitro and ex vivo anticoagulant and profibrinolytic effects of fondaparinux , 2003, Journal of thrombosis and haemostasis : JTH.

[24]  G. Dickneite,et al.  Development of an Anti-Bleeding Agent for Recombinant Hirudin Induced Skin Bleeding in the Pig , 1998, Thrombosis and Haemostasis.

[25]  G. Raskob,et al.  Hemorrhagic complications of anticoagulant treatment. , 2004, Chest.

[26]  N. Carlson,et al.  Reversal of a potent investigational anticoagulant: idraparinux with recombinant factor VIIa. , 2005, The American journal of medicine.

[27]  R. Peters,et al.  Recombinant factor VIIa reverses the anticoagulant effect of the long‐acting pentasaccharide idraparinux in healthy volunteers , 2004, British journal of haematology.

[28]  R. Slappendel,et al.  Treatment of postoperative bleeding after fondaparinux with rFVIIa and tranexamic acid. , 2005, The Netherlands journal of medicine.

[29]  H G Watson,et al.  Guidelines on oral anticoagulation (warfarin): third edition – 2005 update , 2006, British journal of haematology.

[30]  R. Peters,et al.  The impact on coagulation of an intravenous loading dose in addition to a subcutaneous regimen of low-molecular-weight heparin in the initial treatment of acute coronary syndromes. , 2003, Journal of the American College of Cardiology.

[31]  B. Eriksson,et al.  Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. , 2002, Archives of internal medicine.

[32]  J. Hirsh,et al.  The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. , 2004, Chest.

[33]  G. Dickneite Prothrombin complex concentrate versus recombinant factor VIIa for reversal of coumarin anticoagulation. , 2007, Thrombosis research.

[34]  H. Naritomi,et al.  Predisposing factors for enlargement of intracerebral hemorrhage in patients treated with warfarin. , 2003, Thrombosis and haemostasis.

[35]  B. Sullenger,et al.  Nucleic acid aptamers in therapeutic anticoagulation , 2005, Thrombosis and Haemostasis.

[36]  G. Raskob,et al.  Fondaparinux or Enoxaparin for the Initial Treatment of Symptomatic Deep Venous Thrombosis , 2004, Annals of Internal Medicine.

[37]  A. Hoeft,et al.  Efficacy and Safety of Heparinase I versus Protamine in Patients Undergoing Coronary Artery Bypass Grafting with and without Cardiopulmonary Bypass , 2005, Anesthesiology.

[38]  R. Linhardt,et al.  Heparinase I acts on a synthetic heparin pentasaccharide corresponding to the antithrombin III binding site. , 2000, Thrombosis research.

[39]  M. Wolzt,et al.  Effect of recombinant factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteers , 2004, Thrombosis and Haemostasis.

[40]  B. Sullenger,et al.  Blocking the Initiation of Coagulation by RNA Aptamers to Factor VIIa , 2000, Thrombosis and Haemostasis.

[41]  H. Büller,et al.  Ability of Recombinant Factor VIIa to Generate Thrombin During Inhibition of Tissue Factor in Human Subjects , 2001, Circulation.

[42]  A. Daud,et al.  Synthetic Heparin Pentasaccharide Depolymerization by Heparinase 1: Molecular and Biological Implications , 2001, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[43]  C. Kessler,et al.  Reversal of Warfarin-Induced Excessive Anticoagulation with Recombinant Human Factor VIIa Concentrate , 2002, Annals of Internal Medicine.

[44]  F. Rosendaal,et al.  Emergency Oral Anticoagulant Reversal: The Relative Efficacy of Infusions of Fresh Frozen Plasma and Clotting Factor Concentrate on Correction of the Coagulopathy , 1997, Thrombosis and Haemostasis.

[45]  S. Schulman Care of Patients Receiving Long-Term Anticoagulant Therapy , 2003 .

[46]  T. Brott,et al.  Recombinant factor VIIa for rapid reversal of warfarin anticoagulation in acute intracranial hemorrhage. , 2004, Mayo Clinic proceedings.

[47]  J. D. San Antonio,et al.  Novel concatameric heparin-binding peptides reverse heparin and low-molecular-weight heparin anticoagulant activities in patient plasma in vitro and in rats in vivo. , 2004, Blood.

[48]  G. Dehmer,et al.  Recombinant platelet factor 4 for heparin neutralization. , 2004, Seminars in thrombosis and hemostasis.

[49]  Persist investigators A novel long‐acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation , 2004, Journal of thrombosis and haemostasis : JTH.